It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Limited Metastatic Breast Cancer Treatment Study

Clinical Trial Title: 
A stage IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.
Clinical Trial Protocol ID: 
15082104
Clinical Trial Investigator Name: 
Katherine L. Griem, MD
Clinical Trial Protocol Description: 

This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited metastatic) that are previously untreated. Standard of care therapy comprising chemotherapy, hormonal therapy, biological therapy, and others may help stop the spread of tumor cells. Radiation therapy and/or surgery is usually only given with standard of care therapy to relieve pain; however, in patients with limited metastatic breast cancer, stereotactic radiosurgery, also known as stereotactic body radiation therapy, may be able to send x-rays directly to the tumor and cause less damage to normal tissue and surgery may be able to effectively remove the metastatic tumor cells. It is not yet known whether standard of care therapy is more effective with stereotactic radiosurgery and/or surgery in treating limited metastatic breast cancer.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have metastatic breast cancer.
  • Have ≤ 2 sites of metastases.

You will be excluded from the study if any of the following criteria apply to you:

  • Have local regional recurrence.
  • Have brain metastases.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Breast Cancer
Contact Phone: 
(312) 942-0836
Contact Name: 
Adrianne Kajmowicz